- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Additional Immunotherapies on the Horizon for LS-SCLC
Panelists discuss how atezolizumab is being investigated in the NRG-LU005 trial for limited-stage small cell lung cancer (SCLC), comparing its trial design with that of the ADRIATIC study, while also exploring the potential benefits of using a single immunotherapy across all SCLC stages and considering treatment strategies for patients who progress from limited-stage to extensive-stage disease while on immunotherapy.
EP: 1.Introduction: Risk Factors and Characteristics Defining SCLC
EP: 2.Established Multidisciplinary Therapies for SCLC
EP: 3.Immunotherapies for Extensive-Stage SCLC
EP: 4.Introducing Bispecifics for Extensive-Stage SCLC
EP: 5.Standard of Care Durvalumab for Limited-Stage SCLC
EP: 6.Additional Immunotherapies on the Horizon for LS-SCLC
EP: 7.Payer and Patient Education Considerations for SCLC
EP: 8.Biomarker Discovery and Exploration for SCLC
EP: 9.Key Takeaways on Recent Advances in SCLC
EP: 10.Therapies Beyond the Front Line for SCLC
EP: 11.Timing and Urgency Considerations in SCLC
Atezolizumab is also being investigated in the NRG-LU005 trial in patients with limited-stage small cell lung cancer (SCLC).
- What potential role could atezolizumab have in patients with limited-stage disease?
- What is the design of this trial?
- How does the trial design differ from the ADRIATIC trial?
Are there synergies or efficiencies in using a single immunotherapy in all stages of SCLC?
If a patient progresses from limited-stage to extensive-stage disease on immunotherapy, do you switch therapies or continue the same regimen?
